BillionToOne, Inc. (BLLN) Stock Analysis and Metrics

BillionToOne

NASDAQ: BLLN

$123.22 ▼ -3.55 (-2.80%)

At close: Jul 13, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap5.62 Bn

P/E311.82

P/S16.20

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)8.92 Mn

Revenue Growth (1y) (Qtr)83.82

Add ratio to table…

About

BillionToOne, Inc. is a molecular diagnostics company that has developed a single‑molecule next‑generation sequencing platform to enable ultra‑sensitive detection of genetic markers from cell‑free DNA, focusing on prenatal and oncology applications.

The company generates revenue primarily by selling its prenatal and oncology diagnostic tests to healthcare providers and receiving reimbursement from insurance companies, government programs such as Medicare and Medicaid, and direct patient payments. Its product portfolio includes the UNITY suite for fetal risk assessment, aneuploidy screening, RhD status, and fetal antigen detection, as well as the Northstar Select and Northstar Response tests for cancer therapy selection and tumor burden monitoring.

The company operates through the following segments:

• Prenatal: This segment provides non‑invasive prenatal testing products, including the UNITY portfolio for fetal risk assessment, aneuploidy screening, RhD status, and fetal antigen detection, using cell‑free DNA from a single maternal blood draw.

• Oncology: This segment provides liquid biopsy tests for cancer therapy selection and response monitoring, including Northstar Select for mutation detection and Northstar Response for tumor burden measurement, using blood‑based analysis of circulating tumor DNA.

Within the molecular diagnostics industry, BillionToOne holds a differentiated position due to its proprietary single‑molecule next‑generation sequencing technology, which offers greater sensitivity and multiplexing capability than traditional next‑generation sequencing and digital droplet PCR assays used by competitors such as Illumina (through Verinata), Laboratory Corporation of America Holdings, Myriad Genetics, Natera, and Quest Diagnostics in the prenatal market, and Caris Life Sciences, Foundation Medicine (Roche), Guardant Health, NeoGenomics, and Tempus AI in the oncology market. The company’s competitive advantages include its quantitative counting tokens that enable absolute quantification at the single‑molecule level, a patented technology platform that reduces sequencing costs, and a growing body of clinical evidence supporting its tests as potential standards of care.

The company serves obstetricians‑gynecologists, maternal‑fetal medicine specialists, genetic counselors, and other prenatal care providers for its prenatal tests, and oncologists, cancer treatment centers, and hospitals for its oncology tests. Specific partners and collaborators referenced in the filing include Johnson & Johnson, Allegheny Health Network, the University of California San Diego, the University of Florida, the University of Miami, and the Fred Hutchinson Cancer Center.

Investment Thesis

▲ Bull case

BillionToOne's recent achievement of securing an in-network contract with Anthem, bringing total contracted lives to approximately 300 million and covering over 90% of the U.S. population, represents a fundamental shift in market access that is underappreciated by the current stock valuation. This dual in-network status with both UnitedHealthcare and Anthem creates a powerful network effect that significantly reduces friction for physician adoption and patient access, directly supporting the company's ability to sustain ASP expansion beyond temporary seasonal fluctuations. While management acknowledged the Anthem contract as effective immediately, the full impact of predictable, higher reimbursement rates across such a vast covered population is not yet reflected in current trading multiples, especially given the company's history of sequential ASP growth even during typical coinsurance/deductible resets. This structural improvement in payer relationships de-risks future revenue predictability and provides a durable foundation for margin expansion, particularly as higher ASP oncology tests like NorthStar Response gain traction pending Medicare coverage.
The Unity Confirm product launch, though positioned by management as having minimal direct revenue contribution due to its narrow eligibility (0.5%-1% of high-risk NIPT results), contains an underrecognized catalyst for prenatal volume growth through increased platform differentiation and customer lock-in. By making Unity Confirm exclusively available only after a Unity Aneuploidy screening test, the company has created a powerful referral mechanism that incentivizes providers to standardize on BillionToOne's frontline NIPT offering to access the confirmation test when needed. This strategic design transforms Unity Confirm from a niche follow-up test into a volume driver for the core Unity Aneuploidy platform, potentially accelerating adoption in competitive accounts where providers seek to avoid sending samples to multiple vendors. The lack of discussion around this network effect in the Q&A suggests the market is overlooking how this product could significantly increase prenatal test volume retention and conversion rates beyond the stated eligibility window.
Despite oncology revenue growing nearly 400% year-over-year to an annualized run rate of $43 million, the market is failing to appreciate the operating leverage embedded in this segment as scale increases, particularly given that COGS per test decreased 5% sequentially and only increased 1% year-over-year despite a higher oncology mix. This counterintuitive cost control—achieved while launching complex products like CH and managing a more expensive test mix—demonstrates successful early-stage scale benefits in oncology that contradict assumptions about margin dilution from faster-growing oncology. With gross margins already at 73% and management targeting long-term margins above 75% for both segments, the current profitability profile appears sustainable and underleveraged, especially considering the company operates at less than 10% of the accumulated deficit of its public competitors while delivering GAAP operating margins of 16% and adjusted EBITDA margins of 24%.

BillionToOne's recent achievement of securing an in-network contract with Anthem, bringing total contracted lives to approximately 300 million and covering over 90% of the U.S. population, represents a fundamental shift in market access that is underappreciated by the current stock valuation. This dual in-network status with both UnitedHealthcare and Anthem creates a powerful network effect that significantly reduces friction for physician adoption and patient access, directly supporting the company's ability to sustain ASP expansion beyond temporary seasonal fluctuations. While management acknowledged the Anthem contract as effective immediately, the full impact of predictable, higher reimbursement rates across such a vast covered population is not yet reflected in current trading multiples, especially given the company's history of sequential ASP growth even during typical coinsurance/deductible resets. This structural improvement in payer relationships de-risks future revenue predictability and provides a durable foundation for margin expansion, particularly as higher ASP oncology tests like NorthStar Response gain traction pending Medicare coverage.
The Unity Confirm product launch, though positioned by management as having minimal direct revenue contribution due to its narrow eligibility (0.5%-1% of high-risk NIPT results), contains an underrecognized catalyst for prenatal volume growth through increased platform differentiation and customer lock-in. By making Unity Confirm exclusively available only after a Unity Aneuploidy screening test, the company has created a powerful referral mechanism that incentivizes providers to standardize on BillionToOne's frontline NIPT offering to access the confirmation test when needed. This strategic design transforms Unity Confirm from a niche follow-up test into a volume driver for the core Unity Aneuploidy platform, potentially accelerating adoption in competitive accounts where providers seek to avoid sending samples to multiple vendors. The lack of discussion around this network effect in the Q&A suggests the market is overlooking how this product could significantly increase prenatal test volume retention and conversion rates beyond the stated eligibility window.
Despite oncology revenue growing nearly 400% year-over-year to an annualized run rate of $43 million, the market is failing to appreciate the operating leverage embedded in this segment as scale increases, particularly given that COGS per test decreased 5% sequentially and only increased 1% year-over-year despite a higher oncology mix. This counterintuitive cost control—achieved while launching complex products like CH and managing a more expensive test mix—demonstrates successful early-stage scale benefits in oncology that contradict assumptions about margin dilution from faster-growing oncology. With gross margins already at 73% and management targeting long-term margins above 75% for both segments, the current profitability profile appears sustainable and underleveraged, especially considering the company operates at less than 10% of the accumulated deficit of its public competitors while delivering GAAP operating margins of 16% and adjusted EBITDA margins of 24%.

▼ Bear case

BillionToOne's guidance relies heavily on ASP expansion from new payer contracts, yet the company provided no specific timeline or certainty for Medicare coverage of NorthStar Response, which management identified as a key driver for material oncology ASP increases, instead targeting only a vague "year-end" milestone that carries significant execution risk given the historical unpredictability of MolDX and CMS coverage decisions. The absence of concrete progress updates on this critical catalyst during the Q&A—despite direct questioning about MolDX timelines—suggests potential delays are being underestimated, and any slippage into 2027 would directly undermine the ASP uplift assumption embedded in the raised 2026 revenue guidance of $445-$465 million, leaving growth dependent solely on volume which showed only 44% year-over-year increase in Q1.
The company's impressive gross margin expansion to 73% may not be sustainable as the oncology business scales faster than prenatal, particularly since management acknowledged that oncology currently has lower margins due to lower volume scale and lack of Medicare Response coverage, creating a drag on overall profitability that could intensify with the 25% sequential oncology volume growth observed in Q1. While prenatal margins remain strong, the long-term target of maintaining gross margins above 70% depends on offsetting oncology's margin profile through prenatal ASP growth and COGS reductions, yet the company provided no evidence that oncology-specific COGS per test is declining at a sufficient rate to counteract its faster growth, raising concerns that margin expansion could stall or reverse as oncology represents an increasing share of the test mix without concomitant reimbursement improvements.
Accounts receivable increased significantly in Q1 due to timing of new contracts, with management attributing roughly half of the rise to delayed reimbursement from recently signed payer agreements, and while they expect normalization by Q3, the lack of discussion around worsening collection trends or increasing days sales outstanding (DSO) hides a potential working capital strain that could emerge if payer contract implementations face delays or if reimbursement cycles lengthen under new in-network agreements. This risk is amplified by the company's reliance on true-up revenue—which contributed $9.2 million in Q1 and is excluded from future guidance—suggesting that underlying billing and collections processes may not yet be fully optimized at scale, and any persistent AR elevation could constrain free cash flow growth despite strong reported operating income of $17.8 million and operating cash flow of only $11.0 million after capex.

BillionToOne's guidance relies heavily on ASP expansion from new payer contracts, yet the company provided no specific timeline or certainty for Medicare coverage of NorthStar Response, which management identified as a key driver for material oncology ASP increases, instead targeting only a vague "year-end" milestone that carries significant execution risk given the historical unpredictability of MolDX and CMS coverage decisions. The absence of concrete progress updates on this critical catalyst during the Q&A—despite direct questioning about MolDX timelines—suggests potential delays are being underestimated, and any slippage into 2027 would directly undermine the ASP uplift assumption embedded in the raised 2026 revenue guidance of $445-$465 million, leaving growth dependent solely on volume which showed only 44% year-over-year increase in Q1.
The company's impressive gross margin expansion to 73% may not be sustainable as the oncology business scales faster than prenatal, particularly since management acknowledged that oncology currently has lower margins due to lower volume scale and lack of Medicare Response coverage, creating a drag on overall profitability that could intensify with the 25% sequential oncology volume growth observed in Q1. While prenatal margins remain strong, the long-term target of maintaining gross margins above 70% depends on offsetting oncology's margin profile through prenatal ASP growth and COGS reductions, yet the company provided no evidence that oncology-specific COGS per test is declining at a sufficient rate to counteract its faster growth, raising concerns that margin expansion could stall or reverse as oncology represents an increasing share of the test mix without concomitant reimbursement improvements.
Accounts receivable increased significantly in Q1 due to timing of new contracts, with management attributing roughly half of the rise to delayed reimbursement from recently signed payer agreements, and while they expect normalization by Q3, the lack of discussion around worsening collection trends or increasing days sales outstanding (DSO) hides a potential working capital strain that could emerge if payer contract implementations face delays or if reimbursement cycles lengthen under new in-network agreements. This risk is amplified by the company's reliance on true-up revenue—which contributed $9.2 million in Q1 and is excluded from future guidance—suggesting that underlying billing and collections processes may not yet be fully optimized at scale, and any persistent AR elevation could constrain free cash flow growth despite strong reported operating income of $17.8 million and operating cash flow of only $11.0 million after capex.

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password